Pathogenesis of gout: Exploring more therapeutic target

Int J Rheum Dis. 2024 Apr;27(4):e15147. doi: 10.1111/1756-185X.15147.

Abstract

Gout is a chronic metabolic and immune disease, and its specific pathogenesis is still unclear. When the serum uric acid exceeds its saturation in the blood or tissue fluid, it is converted to monosodium urate crystals, which lead to acute arthritis of varying degrees, urinary stones, or irreversible peripheral joint damage, and in severe cases, impairment of vital organ function. Gout flare is a clinically significant state of acute inflammation in gout. The current treatment is mostly anti-inflammatory analgesics, which have numerous side effects with limited treatment methods. Gout pathogenesis involves many aspects. Therefore, exploring gout pathogenesis from multiple perspectives is conducive to identifying more therapeutic targets and providing safer and more effective alternative treatment options for patients with gout flare. Thus, this article is of great significance for further exploring the pathogenesis of gout. The author summarizes the pathogenesis of gout from four aspects: signaling pathways, inflammatory factors, intestinal flora, and programmed cell death, focusing on exploring more new therapeutic targets.

Keywords: gout flare; inflammatory factors; intestinal flora; programmed cell death; signaling pathways.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Gastrointestinal Microbiome* / drug effects
  • Gout Suppressants* / therapeutic use
  • Gout* / drug therapy
  • Humans
  • Inflammation Mediators / metabolism
  • Signal Transduction*
  • Uric Acid* / blood
  • Uric Acid* / metabolism

Substances

  • Uric Acid
  • Gout Suppressants
  • Inflammation Mediators
  • Anti-Inflammatory Agents